Conference on Retroviruses and Opportunistic Infections (CROI 2024)
Denver, Colorado 03 March 2024 - 06 March 2024
Intramuscular injection preferable to IV infusion of ibalizumab for PWH
Ibalizumab delivered via intramuscular (IM) injection is not only safe and well-tolerated but also succeeds in viral suppression among heavily treatment experienced (HTE) people living with HIV (PWH), making IM the preferred method of administration among participants of the TMB-302 study.
Low-dose semaglutide spurs MASLD regression in people with HIV
Treatment with low-dose semaglutide helps reduce the severity of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV, according to data from the single-arm phase IIb ACTG A5371 trial.
Is ART-free remission feasible in children born with HIV who received ART very early in life?
In the IMPAACT* P1115 study presented at CROI 2024, four children who received antiretroviral therapy (ART) for HIV very early in life remained free of detectable HIV for over a year after a break in their ART regimen.
Novel investigational combo a breakthrough in HIV treatment?
Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).